Stocksigma LogoStocksigma Logo

Evonile Pharma Reports Q2 FY27 Results with Exceptional Loss

Evonile Pharma posted a net loss of ₹775.4m for the quarter ended 30th Sep'26, down from a net profit of ₹242.2m YoY and ₹322.1m QoQ

Evonile Pharma Reports Q2 FY27 Results with Exceptional Loss

Novartis India Ltd · Financial Result · 04 Nov 2026, 12:53 am

Evonile Pharma Reports Q2 FY27 Results with Exceptional Loss Evonile Pharma posted a net loss of ₹775.4m for the quarter ended 30th Sep'26, down from a net profit of ₹242.2m YoY and ₹322.1m QoQ. Revenue from operations dropped 37.95% YoY to ₹560.5m. The performance was severely impacted by an exceptional item of ₹682.6m, primarily relating to ₹610.0m from the termination of distribution arrangements with a major customer. Additionally, the company acquired trademark assets for ₹12,900.0m and approved raising up to ₹9,000.0m via a rights issue.

Original exchange filing (PDF)

More announcements from Novartis India Ltd

All Novartis India Ltd announcements